RE:WOW LOOK WHAT I JUST FOUND !Excellent find. By the looks of it management has been in active negotiations with pharmaceutical companies since Oct 2016, Sounds like this could happen this coming month so we might not be waiting all that long for the partnership. Very exciting indeed.
Just thought I would post this section from the Oct 2016 release for the convenience of others. We definitely have a winner here. Glad to be a shareholder.
*********************************************************************
Primary Activities for the Next Twelve Months
Initiate Two Additional Phase 2 Trials for Lead Drug, ATB-346
We are gearing up to initiate two larger Phase 2 clinical studies to support our goal of reaching a partnering event with a global pharmaceutical company within 18 months. The first Phase 2 study will be a placebo-controlled dose-ranging trial to determine the lowest effective dose of ATB-346. The second Phase 2 study will validate the GI safety advantage of ATB-346 versus naproxen, one of the most widely used medications for treating osteoarthritis. These clinical studies are important for our global partnering strategy and Antibe intends to judiciously engage large, global pharmaceutical firms in dialogue upon completion of these trials.
Pre-clinical Studies for Second Pipeline Drug, ATB-352
There is an urgent need for a safer, non-addictive pain-killer for severe pain in the wake of a surge in drug overdose deaths related to opioid abuse. Antibe recently confirmed the non-addictive properties of ATB-352, a ‘stronger’ NSAID, targeting the significant market for severe, acute pain. Antibe is presently evaluating the clinical development strategy for ATB-352 and, due to its short-term use, anticipates its development timeline will be considerably accelerated as compared to that for a chronic-use drug such as ATB-346. We anticipate commencing pre-clinical toxicology studies next year.
Pursue Partnering Opportunities with Regional Pharma
Antibe is strategically seeking regional partnering opportunities to provide non-dilutive sources of funding and monetize its drug platform through royalty and milestone revenue. Antibe is presently in active discussions with pharmaceutical companies in regions that represent smaller market opportunities (i.e., outside of the United States and the ‘big five’ of Western Europe).
Continue to Execute Citagenix Global Growth Strategy
Citagenix is now poised to grow its global market share and we are genuinely excited about 2017 and beyond. Earlier this month we launched a U.S. growth initiative that is essential to our footprint expansion strategy; we now have the first set of tools to effectively compete and grow market share in the most important market for dental biologics and expect to see our U.S. sales ramp through 2017. In addition, while we will continue to source and in-license high-quality biologics, we are cultivating a new focus on higher-return proprietary opportunities. We have identified two new product opportunities that have best-in-class potential and could see regulatory clearance in 2017.
Growing Shareholder Value
We believe that tremendous value of Antibe resides in our patent-protected, independently-validated hydrogen sulfide-releasing technology and the quality of the science behind our pipeline and drug development platform. We also believe that 2017 will be a pivotal year for our lead drug, ATB-346, as we initiate two more Phase 2 studies to support a potential global partnering event within 18 months. Furthermore, we have augmented the risk-return profile of Antibe through the acquisition of our revenue-generating commercial division in regenerative medicine. Antibe remains unique in the Canadian capital markets as a biotechnology company with blockbuster potential that is de-risked by a commercial platform poised for global growth.
Thank you for your ongoing support.
Sincerely yours,
Daniel Legault, CEO
*********************************************************
Jaaghosn wrote: I was reading a new realease from antibe from end of October 2016, and in the article It mentions more than once that they'll be looking for a partnering event with a global pharmaceutical company within 18 months. Well, April 2018 will be the 18th month. Hold on to those shares tight, great news could be right around the corner.
https://www.antibethera.com/2016/10/25/antibe-therapeutics-announces-ceo-letter-to-shareholders/